East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Mycophenolate Mofetil Capsules USP, 250 mg. Aurobindo Pharma’s Mycophenolate Mofetil Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), CellCept Capsules manufactured by Roche Palo Alto LLC.

Mycophenolate Mofetil Capsules are indicated for:

• The prophylaxis of organ rejection, in recipients of allogeneic kidney, heart or liver transplants in combination with other immunosuppressants.